MAPK8 and prostate carcinoma: In contrast, AZA1 treatment caused no changes in phosphorylation of the potential Rac1 effectors ERK, JNK or p38 (data not shown), indicating that activation of these MAPK pathways is not affected by Rac1 and Cdc42 inhibition in 22Rv1 prostate cancer cells.